How gut bacteria affect arthritis and joint health
Studies on gut microbiome-joint connections in arthritis
This work looks at whether changing gut bacteria with a prebiotic fiber or a probiotic can lower inflammation and protect joints in people with obesity-related osteoarthritis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11308429 on NIH RePORTER |
What this research studies
You would be hearing about research that links an unhealthy balance of gut bacteria to inflammation that reaches the knee and speeds up osteoarthritis in people with obesity. In lab models, researchers corrected that imbalance using an indigestible prebiotic fiber called oligofructose and a beneficial bacterium called Bifidobacterium pseudolongum, which reduced gut and joint inflammation and protected knees. The team is digging into how microbial metabolites and immune cells like macrophages and B cells drive joint damage and how changing the microbiome interrupts that process. The goal is to move findings toward approaches that could someday be tested in people with obesity-related knee OA.
Who could benefit from this research
Good fit: Ideal candidates would be adults with obesity-associated knee osteoarthritis or people at high risk for OA because of obesity.
Not a fit: People whose arthritis is caused primarily by autoimmune diseases like rheumatoid arthritis or by isolated traumatic joint injury may not benefit from microbiome-targeted treatments.
Why it matters
Potential benefit: If successful, this work could lead to new dietary supplements or probiotic strategies that lower joint inflammation and slow or prevent osteoarthritis in people with obesity.
How similar studies have performed: Previous animal studies showed that oligofructose supplementation and B. pseudolongum reduced gut and joint inflammation and protected knees from OA, but human trials are limited so clinical benefit in people is still unproven.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Zuscik, Michael J — University of Colorado Denver
- Study coordinator: Zuscik, Michael J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.